BMGFGrants

		BMGFGrants			
Updated 15 November, 20	021				
GRANT ID	GRANTEE	PURPOSE	DATE COMMITTED DURATION (MONTHS	,	
INV-031449	Cancer Hospital, Chinese Academy of Medical Sciences	to fund the implementation research, planning and technical assistance of implementing the pilots of HPV EPI introduction and cervical cancer elimination in cities and low resource regions in China	2021-11 22		
NV-034472	Fudan University Education Development Foundation, Shanghai	to support a research of bacterial infection surveillance and evaluate the vaccine impact to the population of children and the elderly in community post Pneumococcal Conjugate Vaccine (PCV) introduction in children	2021-11 10		
INV-035022	Chinese Preventive Medicine Association	to advocate for evidence-based policies and scale up new TB control models to improve prevention and control of TB	2021-11 34		
INV-004143	Beijing Normal University	to organize a series of seminars to collect and consolidate researchers and practitioners' feedback on the implementation of Charity Law to help policy makers working on the Charity Law amendment gain a full and fair view		7 50000	
INV-033236	Institute of Crop Sciences, Chinese Academy of Agricultural Sciences	to leverage China's experience in rice research and production accumulated to help African countries establish rice seed system that support productivity growth in rice commodities and maintain long term food security and			
INV-031020	China Science and Technology Exchange Center	to enhance China's research and development contribution to global health and development by strengthening partnerships with the government, industry, and academia		1 150000	
INV-035302	Tsinghua University	To provide scientific evidences about new vax introduction and the optimization of immunization service to proactively address issues of vaccine coverage and scheduling challenges when EPI expands	2021-09		
INV-035190	China Agricultural University	to build an enabling environment for supporting China's engagement in global health and development as a global public good provider with the ultimate goal of helping those who are suffering from infectious diseases, hung			
INV-035024	Peking University	to support establish the methodology of the pharmacovigilance real world research to improve China's pharmacovigilance capacity	2021-09 4		
INV-036000	China Primary Health Care Foundation	to drive public awareness of ISO-compliant non-sewer sanitation technology's contribution to public health to facilitate industry development and mass adoption in China for the benefit of poor people living in underserved research.			
INV-027420	Institute of Microbiology, Chinese Academy of Sciences	to support the screening and evaluation of adjuvants and technical platforms for developing universal vaccine antigen (s) and vaccine (s) protecting Pandemic in the future	2021-09		
INV-034554	Duke Kunshan University	to support the exploration of innovative solution on implementation of vaccine introductions and improvement of the immunization programs at the national and regional levels	2021-09		
INV-023665	Academy of Agricultural Planning and Engineering, Ministry of Agriculture and Rural Affairs of the People's Republic of China	to fund demonstration platform in China for showcasing single-unit and multi-unit reinvented toilets (RT), and to validate the commercial and market acceptance of RT systems.	2021-09 2		
INV-035442	University of Chinese Academy of Sciences	to support research on R&D related policies, data regulations, data management, biomedical safety, and biomedical ethics in order to promote global health R&D and mitigate possible risks	2021-09		
INV-034871	National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research	to apply for South-South Cooperation Assistance Fund to fill in Global Fund's gap on SMC supply for Children under five in one African country in Sahel region	2021-09		China
INV-035441	Shanghai Center of Biomedicine Development	To accelerate vaccine development in Shanghai and Yangzi river Delta to address global health challenges in China and the world	2021-08	8 2650000 0	China
INV-034878	Beijing Qiyue Center for Philanthropy	to generate systemic indicators for nonprofits projects, to make it possible for collecting comparable data across nonprofits to generate high quality result/impact analysis that inform giving decisions	2021-08	1 149997	China
INV-031019	The Third People's Hospital of Shenzhen	to support the 3rd Global Health Symposium	2021-08	2 100000 0	China
INV-035249	Agricultural Information Institute of Chinese Academy of Agricultural Sciences	to support targeted researches and consensus building activities for the drafting of China-Africa Ag Modernization Plan with the aim of better leveraging China's expertise to facilitate Africa countries' agricultural transformation	c 2021-08 18	8 170410 0	China
INV-035023	Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing)	to support the organization of TB R&D international forum (2022-2024) to enhance the communication of TB R&D for Chinese scientists and international peers, and serve as a platform to promote TB R&D in China	2021-08	6 204465 0	China
INV-004964	PATH Shanghai Representative Office	to establish and maintain a dedicated, capable, and experienced tuberculosis (TB) expert team to provide technical assistance to support TB control in China	2021-08	7 600000	China
INV-034870	Zhongzhi Social Development Promotion Center	to fund roundtable sessions, one-on-one consultations and workshops for UHNWIs, family offices staff and wealth management professionals to facilitate their philanthropic decisions	2021-07	7 149070	China
INV-021880	China Center for Food and Drug International Exchange	to support China's medical products regulatory system to improve its regulatory capacity in pharmacovigilance	2021-07 4	7 3400000	China
INV-031637	National Center for Women and Children's Health, Chinese Center for Disease Control and Prevention	to improve the Children's nutrition and health in poor areas of China	2021-07	0 1286511	China
INV-031761	Development Reimagined	to support African policy makers and leaders as they develop their strategic GH and GD priorities for FOCAC 2021 and beyond and ultimately deliver improved healthcare interventions to underserved populations through st	2021-07	104619	China
INV-031380	Tsinghua University	to produce a discrete, comfortable, low-cost and sustainable menstrual product based on the suction cups of octopi that reversibly adheres inside the vaginal opening to block blood flow and enable controlled release for co	2021-07	7 100000	China
INV-032021	Chinese Association of STD & AIDS Prevention and Control	to support the local CDC system in Liangshan Prefecture for AIDS prevention and reduce the local rate of mother-to-child transmission of AIDS and the rate of new infections	2021-06	1000000	China
INV-030929	China CDC	to support a landscape research on TB vaccines research and development and generate evidence to improve TB vaccine development and use in China	2021-05	100000	China
INV-032621	Asymchem Life Science (Tianjin) Co., Ltd.	to enable a lower cost process for production of new APIs for TB treatment	2021-05	3 164420	China
INV-031301	PATH Shanghai Representative Office	To provide project management and technical assistance to NMPA project management office to ensure that NMPA-Gates Phase II project is implemented in line with the work plan and the outcomes are successfully achiev	2021-05	640000	China
INV-017019	Shanghai Center for Pujiang Innovation Forum	to create a cooperative platform and partnerships among key national and international stakeholders with Shanghai to address global health and global development challenges to ultimately serve the disadvantaged population	i 2021-04 1:	2 150000	China
INV-031017	Shanghai Center of Biomedicine Development	to build up R&D partnership with Shanghai to address global health and agricultural challenges in China and the world	2021-04 24	500000	China
INV-030859	Chinese Academy of International Trade and Economic Cooperation	to enable our grantee to conduct policy analysis and advocacy activities to promote China-Africa collaboration on Foundation's prioritized global health and global development issues at forthcoming FOCAC in 2021	2021-03	2 250000	China
INV-025841	Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences	to design and engineering of a synthetic enzyme pathway from AA to Artemisinin	2021-01 24	800000	China
INV-026361	Wuhan University	to provide scientific evidence to policy makers to lower the price and improve multi-financing policies of TB drugs that lead to improved accessibilities of high quality TB services and reduced financial burden for TB patients	2021-01	7 127650	China
INV-027291	Shanghai Jiao Tong University	To improve global market need for antimalaria treatment supply of artemisinin.	2021-01	8 299920	China
INV-025826	Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing)	To support the Innovation Alliance on Tuberculosis Diagnosis and Treatment to organize an international TB R&D forum to promote TB research in China and communications with international community.	2020-12	6 61855 (China
INV-018912	Peking University	To evaluate the impact of the Malaria Molecular Epi Lab Network Pilot Projects in Sierra Leone and to promote integration and adoption by the local government and China-Africa health cooperation program for project susta	i 2020-12 3	7 300000	China
INV-023808	Peking Union Medical College	to establish a new research and postgraduate education platform of Global Health and Public Health for mitigating the challenges of Women and Children Immunization	2020-11 3	7 594000 0	China
INV-006407	Tsinghua University	to fund practical research, capacity building, community cultivation and issue communication in the GH and GD space with the ultimate goal to help those who are suffering from infectious diseases, hunger and poverty.	2020-11 3-	4 2500000	China
INV-006372	China CDC	to support China CDC to develop and test the tobacco control monitoring indicators and systems and provide technical assistance to the relevant agencies to track the TC progress to better achieve Healthy China Initiative's	2020-11 30	6 750000 0	China
INV-023018	Academy of Agricultural Planning and Engineering, Ministry of Agriculture and Rural Affairs of the People's Republic of China	to establish a demonstration platform to showcase reinvented toilet and other innovative sanitation technologies and to investigate sustainable business models in preparation for industrial-scale adoption to make impact in	2020-11 23	500000	China
INV-023809	Beijing New Sunshine Charity Foundation	to fund a common fund which will engage local private and public founders in a joint effort to set up a grant-making common fund post COVID-19	2020-10 23	635315	China
INV-018013	Shenzhen Health Development and Research Center	to establish the "The Vaccine & Health Research Consortium" to fund and coordinate research on global health in China, with a focus on vaccine and immunization, to accelerate vaccine preventable disease and vaccine del	i 2020-10 20	6 684280	China
INV-019120	Chinese Academy of International Trade and Economic Cooperation	to support China to develop the effective multisectoral collaboration mechanisms for its Development Assistance for Health Program, with China-Africa Malaria program as an exemplar	2020-10 38	5 1082398 (China
INV-006373	Chinese Preventive Medicine Association	To strengthen the research of vaccine safety and pharmacovigilance for COVID-19 vaccine and NIP vaccine in China	2020-10 20	6 1079982	China
INV-023014	Institute of Plant Protection, Chinese Academy of Agricultural Sciences	to generate learning from China's experience in establishing and improving early warning systems for major crops, which can be shared with less developed countries with such needs, especially in Sub-Saharan Africa	2020-10 2	1 349150	China
INV-004142	Beijing Cihong Charity Foundation	to convene leading Chinese Convene Corporate Foundations to adopt and improve impact-data infrastructure and results measurement	2020-09 30	6 200694 0	China
INV-022394	PATH Shanghai Representative Office	to build up regional cooperative platform based on Pujiang Innovation Forum and to create R&D partnerships with Shanghai to address global health and global development challenges in China and the world	2020-09	9 300000	China
INV-017784	PATH Shanghai Representative Office	To create R&D partnerships with Shanghai to address global health and global development challenges in China and the world	2020-09 44	8 2400000	China
INV-022361	Ginkgo Foundation	to provide general operating support	2020-09	2 50000	China
INV-022392	PATH Shanghai Representative Office	to build up R&D partnership with Shanghai to address global health and development challenges in China and the world	2020-09	2 150000 0	China
INV-017021	Shenzhen Health Development and Research Center	to build up regional partnership with Shenzhen for joint efforts to promote local health capacity building and China's engagement in global health	2020-09	5 149866 (China
INV-017788	Foreign Talent Research Center, Ministry of Science and Technology of the People's Republic of China	To research on CEPI and study on China's possible engagement in CEPI.	2020-09	5 100000 0	China
INV-019121	National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention	to support China CDC to evaluate the quality of COVID-19 serological diagnostic reagents in China and provide evidence for scientific use of reagents in clinical diagnosis and epidemiological survey	2020-08	3 71700 0	China
INV-022855	Asymchem Life Science (Tianjin) Co., Ltd.	to enable a lower cost process for production of Remdesivir API	2020-08	5 141000 0	China
INV-004145	Central University of Finance and Economics	to support policy research and advocacy work in China to ensure high quality implementation of existing tax policies and provide opinions for future improvement	2020-08	4 170000 0	China
INV-019124	National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention	to summarize and document Chinese vector control experience and best practice for sharing with malaria epidemic countries	2020-08	5 130000 0	China
INV-018913	National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research	to summarize and share China malaria elimination experience in the past seven decades by documenting, filming and coordinating video shooting on China's efforts	2020-08	3 450000	China
INV-004139	Peking University	to support high quality research to better understand Chinese online donor behavior through big data analysis, sentiment analysis, social network mapping analysis, etc.	2020-08	7 197266 (China
INV-017787	Shanghai Science and Technology Exchange Center	to support a workshop to increase stakeholder's awareness of global health and COVID-19 R&D importance and discuss prioritized R&D and clinical areas in the post-COVID-19 times	2020-08 1		
INV-018302	Tsinghua University	to conduct a qualitative comparative analysis (QCA) of health system and develop a tabletop exercises to improve the response and preparedness to the pandemic	2020-08 24		
OPP1217414	Tsinghua University	to establish a think tank to provide regulatory science research and technical support for vaccine ecosystem building suggestions	2020-08 24		
INV-018666	Beijing Guokr Interactive Technology Media Co. Ltd	to cultivate and empower the digital influencers and create a platform that amplifies the importance of advocating cross-cutting global health and development issues to ultimately help disadvantaged populations facing these			
INV-017715	Beijing Normal University	to provide in-depth and comprehensive research into the philanthropy in China and propose a development plan, by looking into its history, culture background, existing regulatory environment, and future trajectory	2020-07	100000	China
INV-015971	Narada Foundation	to create a more conducive public opinion environment for nonprofits' long-term development and more inclusive policy environment for the sector to help people suffering from diseases, poverty, gender inequality and other	2020-07 20	6 141865	China
INV-003421	China CDC	Support China CDC on Piloting project on building capacity of malaria molecular lab epidemiology network in Sierra Leone	2020-07 45	2 1800000	China
INV-017785	University of Chinese Academy of Sciences	to research on how China better engage in CGIAR led multi-lateral partnership in Ag areas	2020-07 18	100000	China
INV-016183	Peking University	to conduct policy studies to improve China's participation and engagement in global governance regarding public health security and emergency preparedness and responses	2020-06	4 200000	China
INV-006377	Institute of Microbiology, Chinese Academy of Sciences	To support developing assays platform of drug screening and subunit vaccines of coronavirus, which will contribute to product innovation of COVID-19 pandemic control	2020-05	2 359820 (China
INV-005379	Artepharm Co., Ltd., China	to achieve WHO Pre-qualification approval for AS-PQP by Artepharm	2020-05 40	1100812	China
INV-006406	Zhejiang University	to engage China play a bigger role in global governance and to contribute more to GAVI		5 120000 0	
INV-002169	Yangzhou Pharmaceutical Co., Ltd.	To achieve WHO Pre-qualification approval for Yangzhou LNG API.	2020-05		
INV-004900	Capital Medical University	This investment will be used to support policy studies of provider payment and financing of TB services in China	2020-05	580000	China
INV-006379	National Institutes for Food and Drug Control	to support optimizing pseudovirus platforms for COVID-19 product innovation	2020-05	208575	China
INV-006445	Shanghai Zerun Biotechnology Co., Ltd.	to support research and development for COVID-19 response	2020-05	2 1000000	China
INV-005832	China CDC	to support emergency response and evaluation, and prepare China for the potential pandemic, which will not only help disease control and containment but contribute China's experience to global health	2020-05	9 600000	China
	China National Biotech Group Company Limited	to support international collaboration on anti-coronavirus products to increase the availability of safe and effective products for sustainable distribution and their use in China and the foundation's target countries.	2020-04 33	2 400000	China
INV-005837		to support a series of action studies to summarize social organizations' responses at the forefront of COVID-19 relief efforts and the implications for peer organization and future learning	2020-04		China
	Ginkgo Foundation	to support a solide of action stadios to carminatize social organizations responded at the following	The state of the s	057050	China
INV-006278	Ginkgo Foundation Shenzhen Center for Disease Control and Prevention	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment	2020-04	257250	Orinia
INV-006278	-		2020-04 15 2020-04 17		
INV-006278 INV-006376	Shenzhen Center for Disease Control and Prevention	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment		7 300000	China
INV-006278 INV-006376 INV-006277 INV-005838	Shenzhen Center for Disease Control and Prevention Fudan University	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development	2020-04	7 300000 C	China China
INV-006278 INV-006376 INV-006277 INV-005838	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc.	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use	2020-04 1 ¹ 2020-04 2 ²	7 300000 C 1 400000 C 4 1000000 C	China China China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally	2020-04 1 ¹ 2020-04 2 ² 2020-04 2 ⁴	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0	China China China China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China	2020-04 1 2020-04 2 2020-04 2 2020-04 3	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0	China China China China China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital Xi'an Jiaotong University	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China To support epidemiological prediction and risk assessment, which will facilitate an evidence-based decision-making and allocoation of medical resourses during the battle over COVID-19 outbreak	2020-04 1 2020-04 2 2020-04 2 2020-04 3 2020-03 1 2020-03 2	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0	China China China China China China China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694 INV-006104 INV-006105	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China	2020-04 1 2020-04 2 2020-04 2 2020-04 3 2020-03 1 2020-03 2	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0 2 453000 0	China China China China China China China China China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694 INV-006104	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital Xi'an Jiaotong University Sino Biological Inc.	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China To support epidemiological prediction and risk assessment, which will facilitate an evidence-based decision-making and allocoation of medical resourses during the battle over COVID-19 outbreak to support colloidal gold and ELISA diagnosis of COVID-19 to speed up innovation and increase the availability of effective and large-scale products for the sustainable distribution and use in both China and Foundation's tar To support the post-licensure clinical evaluation and comparison studies of nucleic acid detection reagent to demonstrate the key factors impact the sensitivity and specificity of diagnostics reagents of COVID	2020-04 11 2020-04 22 2020-04 24 2020-04 36 2020-03 12 2020-03 22 2020-03 (0)	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0 2 453000 0 2 100000 0 6 200000 0	China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694 INV-006104 INV-006105 INV-006106	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital Xi'an Jiaotong University Sino Biological Inc. Shanghai ZJ Bio-Tech Co., Ltd.	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China To support epidemiological prediction and risk assessment, which will facilitate an evidence-based decision-making and allocoation of medical resourses during the battle over COVID-19 outbreak to support colloidal gold and ELISA diagnosis of COVID-19 to speed up innovation and increase the availability of effective and large-scale products for the sustainable distribution and use in both China and Foundation's tar To support the post-licensure clinical evaluation and comparison studies of nucleic acid detection reagent to demonstrate the key factors impact the sensitivity and specificity of diagnostics reagents of COVID to support innovation of vaccine and Point of Care Testing (POCT) through epitope identification, the modeling outputs of which will facilitate an evidence-based decision-making during the battle over 2019-nCoV outbreak	2020-04 11 2020-04 22 2020-04 24 2020-04 36 2020-03 12 2020-03 22 2020-03 (0)	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0 2 453000 0 2 100000 0 6 200000 0	China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694 INV-006104 INV-006105 INV-006106 INV-005834 INV-005839	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital Xi'an Jiaotong University Sino Biological Inc. Shanghai ZJ Bio-Tech Co., Ltd. Xiamen University AbMax Biotechnology Co., Ltd.	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China To support epidemiological prediction and risk assessment, which will facilitate an evidence-based decision-making and allocoation of medical resourses during the battle over COVID-19 outbreak to support colloidal gold and ELISA diagnosis of COVID-19 to speed up innovation and increase the availability of effective and large-scale products for the sustainable distribution and use in both China and Foundation's tar To support the post-licensure clinical evaluation and comparison studies of nucleic acid detection reagent to demonstrate the key factors impact the sensitivity and specificity of diagnostics reagents of COVID to support innovation of vaccine and Point of Care Testing (POCT) through epitope identification, the modeling outputs of which will facilitate an evidence-based decision-making during the battle over 2019-nCoV outbreak to speed up the innovation and increase the availability of effective and large scale product for sustainable distribution and use in both China and Foundation's target countries	2020-04 11 2020-04 22 2020-04 22 2020-04 36 2020-03 12 2020-03 22 2020-03 (0) 2020-03 (1)	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0 2 453000 0 2 100000 0 6 200000 0 6 100000 0 7 100000 0	China
INV-006278 INV-006376 INV-006277 INV-005838 INV-006261 INV-005374 INV-015694 INV-006104 INV-006105 INV-006106 INV-005834	Shenzhen Center for Disease Control and Prevention Fudan University CanSino Biologics Inc. Tsinghua University Chinese Association of STD & AIDS Prevention and Control Drug Clinical Trial Center in Peking University Third Hospital Xi'an Jiaotong University Sino Biological Inc. Shanghai ZJ Bio-Tech Co., Ltd. Xiamen University	To support serological investigation in Shenzhen to assess resurging risks of COVID-19 or outbreaks and provide guidance on targeted outbreak response measures after the release of containment to support the epidemiology study and identify the high risks of COVID-19 infection, which will contribute to national and international public health intervention strategy and product development to support international collaboration on development of anti-coronavirus vaccines, which will increase the availability of safe and effective vaccines for sustainable, global distribution and use to provide evidence-based recommendations and technical assistance to improve China public health governance and system to better response to the pandemics such as COVID-19 outbreaks, in China and Globally to carry out a series of national level publicity activities to promote HIV/AIDS and TB prevention and control in China to advance the use of novel quantitative methods to support optimal use and approval of drugs in China To support epidemiological prediction and risk assessment, which will facilitate an evidence-based decision-making and allocoation of medical resourses during the battle over COVID-19 outbreak to support colloidal gold and ELISA diagnosis of COVID-19 to speed up innovation and increase the availability of effective and large-scale products for the sustainable distribution and use in both China and Foundation's tar To support the post-licensure clinical evaluation and comparison studies of nucleic acid detection reagent to demonstrate the key factors impact the sensitivity and specificity of diagnostics reagents of COVID to support innovation of vaccine and Point of Care Testing (POCT) through epitope identification, the modeling outputs of which will facilitate an evidence-based decision-making during the battle over 2019-nCoV outbreak	2020-04 11 2020-04 22 2020-04 22 2020-04 36 2020-03 12 2020-03 22 2020-03 (0) 2020-03 (1)	7 300000 0 1 400000 0 4 1000000 0 6 1500000 0 2 453000 0 2 100000 0 6 200000 0 6 100000 0 7 100000 0	China